Provided by Tiger Fintech (Singapore) Pte. Ltd.

Plus Therapeutics, Inc.

0.3022
-0.3578-54.21%
Post-market: 0.3006-0.0016-0.53%19:58 EST
Volume:4.78M
Turnover:1.50M
Market Cap:1.78M
PE:-0.10
High:0.6894
Open:0.6508
Low:0.2400
Close:0.6600
Loading ...

Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall

MT Newswires Live
·
7 hours ago

Plus Therapeutics sees $15M in gross proceeds from private placement

TIPRANKS
·
9 hours ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

THOMSON REUTERS
·
9 hours ago

Plus Therapeutics granted orphan designation for lung cancer treatment

TIPRANKS
·
01 Mar

Plus Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Reuters
·
28 Feb

Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
27 Feb

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients With Leptomeningeal Metastases

THOMSON REUTERS
·
26 Feb

Plus Therapeutics appoints Russell Bradley as president, CNSide

TIPRANKS
·
24 Feb

Plus Therapeutics Announces Leadership Appointments for Its Cnside Diagnostics Subsidiary

THOMSON REUTERS
·
24 Feb

Plus Therapeutics Appoints DR. Michael Rosol as Chief Development Officer

THOMSON REUTERS
·
20 Feb

Plus Therapeutics secures $5.7M financing

TIPRANKS
·
18 Feb

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Dow Jones
·
18 Feb

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

THOMSON REUTERS
·
18 Feb

Plus Therapeutics expands strategic agreement with Telix IsoTherapeutics

TIPRANKS
·
03 Dec 2024

Plus Therapeutics Expands Strategic Agreement With Telix Isotherapeutics Group for Rhenium-186 Radioisotope Supply

THOMSON REUTERS
·
03 Dec 2024

Plus Therapeutics Inc : Jonestrading Cuts Target Price to $10 From $32

THOMSON REUTERS
·
18 Nov 2024